ライフサイエンスコーパス: erectile

1 exual life, while 26% reported impairment in erectile and 22% in ejaculatory function.

2 ffolds repair the defects and recover penile erectile and ejaculation function successfully.

3 ng sexual desire, sexual function, including erectile and ejaculatory function, and sexual satisfacti

4 , the external layer, which supplements both erectile and micturition function, the internal layer, w

5 Urinary incontinence and erectile and sexual dysfunction were each greater with s

6 le lubricating (273 [22.3%]) among women and erectile difficulties (156 [21.7%]) and lack of interest

7 men, the most prevalent sexual problems were erectile difficulties (37%).

8 s associated with ischemic tissue damage and erectile disability.

9 apism, an important but poorly characterized erectile disorder.

10 athway may be a novel therapeutic target for erectile disorders.

11 , 2.04-2.46), hypotension (3.23, 1.85-5.52), erectile dysfunction (1.30, 1.11-1.51), urinary dysfunct

12 9 vs 12.2 per 100 person-years; P = .02) and erectile dysfunction (26.8 vs 19.2 per 100 person-years;

13 d ratio 1.03 [95% CI 0.88-1.21]; p=0.72) and erectile dysfunction (272 [1.86% per annum] vs 302 [2.14

14 3) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100

15 ked at some time had a greater likelihood of erectile dysfunction (age-adjusted odds ratio = 1.42, 95

16 0.008) for participants with first onset of erectile dysfunction (before 1986) at 60 or more, 50-59,

17 he internal pudendal arteries among men with erectile dysfunction (ED) and a suboptimal response to p

18 Chronic heart failure (HF) and erectile dysfunction (ED) are 2 highly prevalent disorde

19 Erectile dysfunction (ED) carries an independent risk fo

20 Pharmacologic treatments for erectile dysfunction (ED) have gained popularity among m

21 Erectile dysfunction (ED) is a common condition affectin

22 Erectile dysfunction (ED) is estimated to affect more th

23 The predominant etiology for erectile dysfunction (ED) is vascular, but limited data

24 This study was designed to determine whether erectile dysfunction (ED) predicts cardiovascular diseas

25 hough there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (C

26 less legs syndrome (RLS) was associated with erectile dysfunction (ED).

27 ers, and both share common risk factors with erectile dysfunction (ED).

28 accounts significantly for the prevalence of erectile dysfunction (ED).

29 degeneration of the cavernous nerve (CN) and erectile dysfunction (ED).

30 osis, which is relevant to the occurrence of erectile dysfunction (ED).

31 treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to de

32 mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2

33 The incidence of erectile dysfunction (IIEF-5 <= 11) at 12 months after s

34 (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, th

35 to enhance sex (p=0.0006), use of drugs for erectile dysfunction (p<0.0001), and 100% condom use (p<

36 lation between cigarette smoking and risk of erectile dysfunction (p(trend) = 0.005).

37 lockbuster status in the treatment of penile erectile dysfunction (PED).

38 nary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]).

39 function tenderness, frequent urination, and erectile dysfunction [ED]) and measures of physical and

40 tudy entry, 2420 men (57%) reported incident erectile dysfunction after 5 years.

41 morbidities may have a significant impact on erectile dysfunction after CaP treatment.

42 d tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are

43 Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, bu

44 Erectile dysfunction after radical therapy for CaP may b

45 iation between cigarette smoking and risk of erectile dysfunction among 7,684 Chinese men aged 35-74

46 Erectile dysfunction and cardiovascular disease share th

47 e the foundation for the strong link between erectile dysfunction and cardiovascular disease.

48 els were used to evaluate the association of erectile dysfunction and cardiovascular disease.

49 etermine associations between stroke-related erectile dysfunction and cerebral ischaemic lesion sites

50 Erectile dysfunction and depression are highly associate

51 l treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life.

52 orts the link between metabolic syndrome and erectile dysfunction and highlights metabolic syndrome a

53 dities associated with prostatectomy, namely erectile dysfunction and incontinence.

54 s showed associations between stroke-related erectile dysfunction and lesion sites in the right occip

55 Erectile dysfunction and low testosterone levels frequen

56 o in improving erectile function in men with erectile dysfunction and low testosterone levels.

57 ic symptoms (constipation, urinary symptoms, erectile dysfunction and orthostatic hypotension) were n

58 odiesterase that is used clinically to treat erectile dysfunction and pulmonary arterial hypertension

59 tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.

60 inary incontinence, anastomotic contracture, erectile dysfunction and rectourethral fistula (RUF) for

61 afety and efficacy of vardenafil in men with erectile dysfunction and untreated mild depression.

62 tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression

63 ectomy, post-operative complications such as erectile dysfunction and urinary incontinence persist at

64 DE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindicat

65 Erectile dysfunction appears to be one of the earliest s

66 ival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those s

67 ng evidence that endothelial dysfunction and erectile dysfunction are linked.

68 risk factors for cardiovascular disease and erectile dysfunction are similar.

69 phosphodiesterase-5 inhibitor treatment for erectile dysfunction associated with antidepressant ther

70 going prostatectomy were more likely to have erectile dysfunction at 2 years (odds ratio, 3.46; 95% C

71 was 0.015 per person-year among men without erectile dysfunction at study entry and was 0.024 per pe

72 Among the 4247 men without erectile dysfunction at study entry, 2420 men (57%) repo

73 at study entry; of these men, 3816 (47%) had erectile dysfunction at study entry.

74 y and was 0.024 per person-year for men with erectile dysfunction at study entry.

75 Men with erectile dysfunction before 1986 were 3.8 times more lik

76 very 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003.

77 nhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascula

78 association is causal, an estimated 22.7% of erectile dysfunction cases (11.8 million cases) among Ch

79 he International Index of Erectile Function (Erectile Dysfunction Domain) score >/= 4 points in >/= 5

80 tes, 477 (21%) used cannabis, 460 (21%) used erectile dysfunction drugs, 453 (20%) used cocaine, 280

81 The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PD

82 tion therapy for ischemic and any stroke and erectile dysfunction for any stroke.

83 llel-group, double-blind study, 280 men with erectile dysfunction for at least 6 months and untreated

84 he technology used intraoperatively, induces erectile dysfunction for most men who undergo the proced

85 is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon

86 Erectile dysfunction has a negative impact on health-rel

87 understanding of the cause and management of erectile dysfunction in CaP survivors.

88 synthase (eNOS) function is associated with erectile dysfunction in diabetes mellitus, but the exact

89 etrospective questionnaire with questions on erectile dysfunction in different time periods.

90 Although no standard management of erectile dysfunction in prostate cancer (CaP) survivors

91 ot support daily use of tadalafil to prevent erectile dysfunction in these patients.

92 Erectile dysfunction is a harbinger of cardiovascular cl

93 Erectile dysfunction is also strongly associated with a

94 Erectile dysfunction is common after radical prostatecto

95 Erectile dysfunction is common among individuals with Pa

96 the influence of CP/CPPS on the incidence of erectile dysfunction is scant.

97 Erectile dysfunction occurred frequently after all treat

98 tain patients who already have some baseline erectile dysfunction or are not candidates for nerve-spa

99 Erectile dysfunction rates are universally high after wh

100 f this work is to review the fundamentals of erectile dysfunction relevant to the postprostatectomy p

101 gression analysis showed that stroke-related erectile dysfunction remained associated with lesions of

102 ased lesion analysis, the difference between erectile dysfunction scores before and after stroke was

103 as brain volumes and the difference between erectile dysfunction scores before and after stroke.

104 In 32 patients (61.5%) erectile dysfunction scores declined after the stroke an

105 Deterioration of erectile dysfunction scores was not associated with pati

106 Erectile dysfunction should prompt investigation and int

107 ata linking lower urinary tract symptoms and erectile dysfunction suggest that lower urinary tract sy

108 vent of oral medication for the treatment of erectile dysfunction the disease has garnered increasing

109 Erectile dysfunction treatment should be considered a co

110 T vs no ADT and 1.35 (95% CI, 1.18-1.53) for erectile dysfunction vs no dysfunction.

111 and hypercholesterolemia, the odds ratio of erectile dysfunction was 1.41 (95% confidence interval (

112 ire; during the fourth biennial examination, erectile dysfunction was assessed with the Brief Male Se

113 After adjustment, incident erectile dysfunction was associated with a hazard ratio

114 rge cohort of men, the authors observed that erectile dysfunction was associated with a higher risk o

115 this question, the authors examined whether erectile dysfunction was associated with Parkinson's dis

116 Multivariate-adjusted odds ratios of erectile dysfunction were 1.27 (95% CI: 0.91, 1.77), 1.4

117 Cigarette smoking and erectile dysfunction were assessed by questionnaire.

118 ica albuginea, is reserved for patients with erectile dysfunction who have not responded to medical t

119 e efforts being made to reduce posttreatment erectile dysfunction, a major morbidity of these therapi

120 phosphodiesterase 5 inhibitor used to treat erectile dysfunction, ameliorates high glucose stimulati

121 ab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a haem

122 rapeutic target for the treatment of asthma, erectile dysfunction, and atherosclerosis.

123 and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are g

124 failure like infertility, low testosterone, erectile dysfunction, and low bone mineral density.

125 apter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD.

126 er symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass.

127 rome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

128 Bowel continence, erectile dysfunction, and social life disturbance were n

129 comorbidities have been reported, including erectile dysfunction, atrial fibrillation, obstructive s

130 such as sildenafil are widely used to treat erectile dysfunction, but growing evidence supports impo

131 Injury of corpus cavernosa results in erectile dysfunction, but its treatment has been very di

132 ole of endothelium in the pathophysiology of erectile dysfunction, cardiovascular disease, and the me

133 Other comorbidities including erectile dysfunction, cardiovascular diseases should als

134 Erectile dysfunction, defined as the consistent inabilit

135 In patients with refractory erectile dysfunction, dexterous and motivated patients r

136 logical conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidn

137 levels such as hot flushes, lack of libido, erectile dysfunction, gynecomastia and bone mineral dens

138 s of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional canc

139 of poor morning erection, low sexual desire, erectile dysfunction, inability to perform vigorous acti

140 or on the individual preferences of men with erectile dysfunction, including ease of use, cost of med

141 Risks of erectile dysfunction, incontinence, and disease recurren

142 applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addit

143 d with abdominal obesity, diabetes mellitus, erectile dysfunction, muscle weakness, and all-cause mor

144 depression, orthostatic hypotension, urinary/erectile dysfunction, PD family history, and the prodrom

145 disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontitis, inflammatory bowel

146 prespecified AEs of interest-muscle-related, erectile dysfunction, sleep disturbance, and cognitive i

147 are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complicat

148 in the advent of PDE5 inhibitors that treat erectile dysfunction, such as Viagra, Levitra, and Ciali

149 We report that two widely-used drugs for erectile dysfunction, tadalafil and vardenafil, trigger

150 duced over 30 years ago for the treatment of erectile dysfunction, technological innovations have con

151 For men with either incident or prevalent erectile dysfunction, the hazard ratio was 1.45 (95% CI,

152 nt, to assess and treat side-effects such as erectile dysfunction, to switch to less costly generic a

153 tonomic features (constipation, hypotension, erectile dysfunction, urinary dysfunction, and dizziness

154 ients presented with urinary incontinence or erectile dysfunction.

155 One patient in each group reported erectile dysfunction.

156 pisodic dry eyes and mouth, hot flashes, and erectile dysfunction.

157 ion, implying unique approaches for treating erectile dysfunction.

158 ccess of PDE5 inhibitors in the treatment of erectile dysfunction.

159 ng would each result in 1 additional case of erectile dysfunction.

160 rted use of medications or other devices for erectile dysfunction.

161 emain a viable tertiary treatment option for erectile dysfunction.

162 such as asthma, cardiovascular diseases, and erectile dysfunction.

163 ibitors in patients with coexisting LUTS and erectile dysfunction.

164 denafil, etc.) are first-line treatments for erectile dysfunction.

165 -eye movement sleep behaviour disorder), and erectile dysfunction.

166 nitourinary complications, incontinence, and erectile dysfunction.

167 ssociation with penile fibrosis and eventual erectile dysfunction.

168 l testing in and pharmacologic management of erectile dysfunction.

169 5 with high specificity and is used to treat erectile dysfunction.

170 diated erectile tissue damage and subsequent erectile dysfunction.

171 ence, renal disease, bladder dysfunction and erectile dysfunction.

172 wer administered dosage for the treatment of erectile dysfunction.

173 cular diseases to pulmonary hypertension and erectile dysfunction.

174 lation between cigarette smoking and risk of erectile dysfunction.

175 age, respectively, relative to those without erectile dysfunction.

176 PDE V inhibitor that is used clinically for erectile dysfunction.

177 ment or prophylaxis exists for posttreatment erectile dysfunction.

178 1a (ABT-724) for the potential treatment of erectile dysfunction.

179 potential risk factor for the development of erectile dysfunction.

180 onent of therapy for men with depression and erectile dysfunction.

181 low quality of life contributes to or causes erectile dysfunction.

182 static hyperplasia are definitely related to erectile dysfunction.

183 This effect has led to its use for treating erectile dysfunction.

184 escribing an association between smoking and erectile dysfunction.

185 and it is this that contributes to or causes erectile dysfunction.

186 unction, and loss of the BK channel leads to erectile dysfunction.

187 836 had previously smoked, and 203 reported erectile dysfunction.

188 ion-making when confronted by a patient with erectile dysfunction.

189 the stroke and therefore had stroke-related erectile dysfunction.

190 get for treating cardiovascular diseases and erectile dysfunction.

191 atic hypotension, sweating abnormalities, or erectile dysfunction.

192 clinical endpoints: late rectal bleeding and erectile dysfunction.

193 raction, such as hypertension, glaucoma, and erectile dysfunction.

194 ated with devastating complications, notably erectile dysfunction.

195 quency, urinary incontinence, proctitis, and erectile dysfunction.

196 l morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy

197 as improvement in the International Index of Erectile Function (Erectile Dysfunction Domain) score >/

198 ostvoid residual volume, International Index Erectile Function (IIEF) score, prostate volume, and pro

199 5-item version of the International Index of Erectile Function (IIEF-5) and ejaculation grading.

200 5-item International Index of Erectile Function (IIEF-5) was also increased at 12 mont

201 re surgery and during follow-up and measured erectile function (International Index for Erectile Func

202 questionnaire and the International Index of Erectile Function (IPSS).

203 the follow-up than were those with very good erectile function (relative risk = 3.8, 95% confidence i

204 and treatment details enables prediction of erectile function 2 years after prostatectomy, external

205 Primary outcome was off-drug spontaneous erectile function 28 to 30 weeks after radiotherapy star

206 d erectile function (International Index for Erectile Function [IIEF] score) and urine flow rates at

207 th first-ever ischaemic strokes, we assessed erectile function after and retrospectively 3 months pri

208 mproved recovery of urinary incontinence and erectile function after open radical prostatectomy.

209 l-wise analysis indicates that deteriorating erectile function after stroke is associated with lesion

210 of patients with unchanged and deteriorated erectile function after stroke.

211 +/- 8.7 versus 11.9 +/- 10.2 (P < 0.05) for erectile function and 6.9 +/- 2.4 versus 5.3 +/- 2.5 (P

212 Significant improvements in erectile function and depression were observed in patien

213 showed associations between deterioration of erectile function and lesion sites in the right occipita

214 ord play an important role in the control of erectile function and male sexual behavior in mammals.

215 ermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003

216 To optimize recovery of erectile function and prevent loss of penile length, pen

217 and endothelial NOS-deficient mice maintain erectile function and reproductive capacity, questioning

218 The critical maneuvers to preserving erectile function are atraumatic dissection of the prost

219 ious and otherwise) and urinary symptoms and erectile function assessed using patient questionnaires.

220 Among men who reported their erectile function before 1986, 200 were diagnosed with P

221 -88%) assigned to receive tadalafil retained erectile function between weeks 28 and 30 compared with

222 sphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability

223 autologous SIS-ADSC grafts maintained better erectile function compared with animals grafted with SIS

224 tributing to male sexual function may impair erectile function depending on the lesion site.

225 conduction, activities of daily living, and erectile function did not show a significant difference

226 ded International Index of Erectile Function erectile function domain and 17-item Hamilton Depression

227 The International Index of Erectile Function erectile function domain score was 22.9 with vardenafil

228 in International Index of Erectile Function erectile function domain score was the most important pr

229 In order to optimize postprostatectomy erectile function during a robotic-assisted radical pros

230 n together, these data suggest that impaired erectile function during the aging process involves incr

231 Endpoints included International Index of Erectile Function erectile function domain and 17-item H

232 The International Index of Erectile Function erectile function domain score was 22.

233 Improvement in International Index of Erectile Function erectile function domain score was the

234 riable logistic regression models predicting erectile function estimated 2-year function probabilitie

235 the standing position and second, achieving erectile function for sexual activity.

236 Participants rated their erectile function in 2000 (with historical reporting fro

237 and young rats for 7 days markedly improved erectile function in aged rats when compared with that i

238 rior to sildenafil plus placebo in improving erectile function in men with erectile dysfunction and l

239 ry goal of radical prostatectomy, preserving erectile function is also tantamount, given the indolent

240 fficacy in motivated patients, the return of erectile function is never guaranteed with nonsurgical m

241 ions but also return him to his preoperative erectile function level.

242 and clinically meaningful improvement in all erectile function parameters.

243 t or after radical prostatectomy to maximize erectile function recovery.

244 dical prostatectomy as a strategy to improve erectile function recovery.

245 radical prostatectomy are of some benefit to erectile function recovery.

246 Participant-reported International Index of Erectile Function response before radiotherapy and at we

247 o hundred forty-two participants with intact erectile function scheduled to receive radiotherapy for

248 d) and aged (20-22 month old) rats underwent erectile function testing in vivo by measuring intracave

249 1027) were used to develop models predicting erectile function that were externally validated among 1

250 Erectile function was also assessed.

251 Erectile function was assessed by means of questionnaire

252 The data demonstrated that erectile function was significantly lower in aged rats t

253 Whether testosterone could improve erectile function without sildenafil was not studied.

254 ostate Symptom Score, International Index of Erectile Function, and Female Sexual Function Index), an

255 that the BK channel has an important role in erectile function, and loss of the BK channel leads to e

256 europathy and endothelial dysfunction impair erectile function, and phosphodiesterase inhibition prod

257 regarding oncologic outcome, continence, and erectile function, as well as some earlier manuscripts t

258 Since it may permanently impair erectile function, it must be managed and treated as soo

259 r ICIQ-MLUTS, and the International Index of Erectile Function, or IIEF-5, questionnaires (P = .58 an

260 Sexual desire, erectile function, overall sexual function scores, partn

261 laxing factors involved in the regulation of erectile function, providing alternative therapeutic tar

262 10) were normal, showing normal voiding and erectile function, respectively.

263 Inhibition of this pathway attenuated erectile function, suggesting that EETs are required for

264 Median overall International Index of Erectile Function-15 (IIEF-15) scores were similar at ba

265 scores of the 5-item International Index of Erectile Function-5 questionnaire.

266 -flow priapism and for restoration of penile erectile function.

267 of the neurovascular bundle responsible for erectile function.

268 raxia enables earlier and better recovery of erectile function.

269 , urinary problems, hot flashes, libido, and erectile function.

270 TA reconstruction procedures and can restore erectile function.

271 in both subjective and objective measures of erectile function.

272 ivities of daily living, quality of life and erectile function.

273 izations, health-related quality of life, or erectile function.

274 after radical prostatectomy have focused on erectile function.

275 tudies examined how these measures relate to erectile function.

276 e surrounding fascia, may hasten recovery of erectile function.

277 ost important predictor for return to normal erectile function.

278 tric oxide, which plays an important role in erectile function.

279 examined associations between flavonoids and erectile function.

280 as significantly increased sexual desire and erectile function.

281 rolling disease while preserving urinary and erectile function.

282 ared with placebo did not result in improved erectile function.

283 mooth muscle tissue is the key to preserving erectile function.

284 ed higher than baseline, although persistent erectile impairment was limited to Caucasian American pa

285 Urinary, bowel, and erectile morbidity rates were 33.8%, 21.0%, and 16.7%, r

286 Erectile morbidity was associated with younger age (P <

287 ed percentage of men reporting posttreatment erectile or ejaculatory problems remained higher than ba

288 aseline and 12 months were noted for IIEF-15 erectile (p=0.042) and orgasmic function (p=0.003).

289 ding bat, Glossophaga soricina, uses dynamic erectile papillae to collect nectar.

290 P-dependent phosphorylation of nNOS mediates erectile physiology, including sustained erection.

291 with CRC the most during the past week were erectile problems (42% of men), trouble hearing (11%), t

292 tudy was to examine the relationship between erectile problems in men and cardiovascular disease (CVD

293 behavior, obesity, energy homeostasis, male erectile response, and blood pressure.

294 n the enzyme and hampering mechanisms of the erectile response.

295 Erectile responses to both cavernous nerve stimulation a

296 avernosal tissue preservation and maintained erectile responses, similar to controls, in a rat model

297 s and evolutionary origin of the spectacular erectile ruff of the frilled dragon (Chlamydosaurus king

298 ed NO release from C6' corrects pathological erectile signaling in mouse models of priapism and sugge

299 30% and 40% in mean diameter in flaccid and erectile states, respectively.

300 tation, is associated with ischemia-mediated erectile tissue damage and subsequent erectile dysfuncti